Osivax and GC Biopharma Sign Global Collaboration Combining OVX836 Nucleoprotein-Targeted Broad-Spectrum Vaccine With GC FLU for Next-Generation Seasonal Influenza
Osivax (clinical-stage French biopharmaceutical) and GC Biopharma (South Korean vaccine maker, KRX: 006280) announced Thursday August 27, 2026 a long-term collaboration to develop and commercialize a next-generation seasonal influenza vaccine candidate combining OVX836 (Osivax's broad-spectrum influenza A vaccine targeting the highly conserved nucleoprotein NP, in Phase 2 development) with GC FLU (GC Biopharma's marketed inactivated influenza vaccine). Osivax receives a non-exclusive sublicensable global license (excluding Japan and Korea) to use GC FLU in combination with OVX836 and will lead global development and commercialization outside South Korea; GC Biopharma retains exclusive Korean rights, receives royalties, and ensures long-term supply of GC FLU. Financial terms were not disclosed. The NP-targeted broad-spectrum approach positions the combination to address the annual antigenic-drift problem that has kept seasonal influenza vaccine efficacy in the 30-60% range and drives interest in peptide- and protein-based broadly conserved epitope vaccines.